Skip to main content
Top
Published in: Journal of Cancer Survivorship 2/2024

Open Access 22-03-2022 | Breast Cancer

Work status changes and associated factors in a nationwide sample of Norwegian long-term breast cancer survivors

Authors: Synne-Kristin Hoffart Bøhn, K. F. Vandraas, C. E. Kiserud, A. A. Dahl, L. Thorsen, M. Ewertz, H. C. Lie, R. Falk, K. V. Reinertsen

Published in: Journal of Cancer Survivorship | Issue 2/2024

Login to get access

Abstract

Purpose

The study aims to describe work status at diagnosis and 8 years post-diagnosis in a nationwide sample of breast cancer survivors (BCSs), and investigate associated and self-reported factors of reduced work status.

Methods

Women aged 20–65 years when diagnosed with stage I–III breast cancer (BC) in 2011 or 2012 were invited to participate in a questionnaire study in 2019 (n = 2803), of whom 49% (n = 1361) responded. For this sub-study, we included 974 BCSs below the legal retirement age in Norway (< 67 years) at survey and with complete work status data. Reduced work status was defined as being in paid work at BC diagnosis and not working at time of survey. Logistic regression analyses were applied to identify factors associated with reduced work status.

Results

Of BCSs who were in paid work at diagnosis (n = 845), 63% maintained their work status to 8 years later. Reduced work status was associated with not living with children (OR .44, 95% CI .24–.82), age (OR 1.16, 95% CI 1.11–1.21), chemotherapy (OR 2.83, 95% CI 1.24–6.61), > 2 comorbid conditions (OR 2.27, 95% CI 1.16–4.32), cognitive function (OR .99, 95% CI .98–.99), fatigue (OR 1.02, 95% CI 1.01–1.03), and neuroticism (OR 1.57, 95% CI 1.00–2.46). BC and late effects were reported as reasons for reduced work status and disability.

Conclusions

The majority of BCSs who were in paid work at diagnosis were working 8 years later.

Implications for Cancer Survivors

Our results suggest a need to focus on fatigue and reduced cognitive function among long-term BCSs, with the ultimate aim of improving work sustainability.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cancer Registry of Norway. Cancer in Norway 2019 — cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2020. Cancer Registry of Norway. Cancer in Norway 2019 — cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2020.
2.
go back to reference DeSantis CE, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–48.PubMedCrossRef DeSantis CE, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–48.PubMedCrossRef
3.
go back to reference van Maarschalkerweerd PEA, et al. Changes in employment status, barriers to, and facilitators of (return to) work in breast cancer survivors 5–10 years after diagnosis. Disabil Rehabil. 2020;42(21):3052–8.PubMedCrossRef van Maarschalkerweerd PEA, et al. Changes in employment status, barriers to, and facilitators of (return to) work in breast cancer survivors 5–10 years after diagnosis. Disabil Rehabil. 2020;42(21):3052–8.PubMedCrossRef
4.
go back to reference Ewertz M, Jensen AB. Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol. 2011;50(2):187–93.PubMedCrossRef Ewertz M, Jensen AB. Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol. 2011;50(2):187–93.PubMedCrossRef
5.
go back to reference Sun Y, Shigaki CL, Armer JM. Return to work among breast cancer survivors: a literature review. Support Care Cancer. 2017;25(3):709–18.PubMedCrossRef Sun Y, Shigaki CL, Armer JM. Return to work among breast cancer survivors: a literature review. Support Care Cancer. 2017;25(3):709–18.PubMedCrossRef
6.
go back to reference Bijker R, et al. Functional impairments and work-related outcomes in breast cancer survivors: a systematic review. J Occup Rehabil. 2018;28(3):429–51.PubMedCrossRef Bijker R, et al. Functional impairments and work-related outcomes in breast cancer survivors: a systematic review. J Occup Rehabil. 2018;28(3):429–51.PubMedCrossRef
7.
go back to reference Boelhouwer IG, Vermeer W, van Vuuren T, The associations between late effects of cancer treatment, work ability and job resources: a systematic review. Int Arch Occup Environ Health, 2020. Boelhouwer IG, Vermeer W, van Vuuren T, The associations between late effects of cancer treatment, work ability and job resources: a systematic review. Int Arch Occup Environ Health, 2020.
8.
go back to reference Sun Y, Shigaki CL, Armer JM. The influence of breast cancer related lymphedema on women’s return-to-work. Womens Health (Lond). 2020;16:1745506520905720.PubMed Sun Y, Shigaki CL, Armer JM. The influence of breast cancer related lymphedema on women’s return-to-work. Womens Health (Lond). 2020;16:1745506520905720.PubMed
9.
10.
go back to reference Cocchiara RA, et al. Returning to work after breast cancer: a systematic review of reviews. Work. 2018;61(3):463–76.PubMedCrossRef Cocchiara RA, et al. Returning to work after breast cancer: a systematic review of reviews. Work. 2018;61(3):463–76.PubMedCrossRef
11.
12.
go back to reference Peipins LA, et al. Employment after breast cancer diagnosis and treatment among women in the sister and the two sister studies. J Occup Rehabil. 2021;31(3):543–51.PubMedPubMedCentralCrossRef Peipins LA, et al. Employment after breast cancer diagnosis and treatment among women in the sister and the two sister studies. J Occup Rehabil. 2021;31(3):543–51.PubMedPubMedCentralCrossRef
13.
go back to reference Hamood R, et al. Work transitions in breast cancer survivors and effects on quality of life. J Occup Rehabil. 2019;29(2):336–49.PubMedCrossRef Hamood R, et al. Work transitions in breast cancer survivors and effects on quality of life. J Occup Rehabil. 2019;29(2):336–49.PubMedCrossRef
14.
go back to reference Schmidt ME, et al. Return to work after breast cancer: the role of treatment-related side effects and potential impact on quality of life. Eur J Cancer Care (Engl). 2019;28(4):e13051.PubMedCrossRef Schmidt ME, et al. Return to work after breast cancer: the role of treatment-related side effects and potential impact on quality of life. Eur J Cancer Care (Engl). 2019;28(4):e13051.PubMedCrossRef
15.
go back to reference Paalman CH, et al. Employment and social benefits up to 10 years after breast cancer diagnosis: a population-based study. Br J Cancer. 2016;114(1):81–7.PubMedPubMedCentralCrossRef Paalman CH, et al. Employment and social benefits up to 10 years after breast cancer diagnosis: a population-based study. Br J Cancer. 2016;114(1):81–7.PubMedPubMedCentralCrossRef
16.
go back to reference Hauglann B, et al. A cohort study of permanently reduced work ability in breast cancer patients. J Cancer Surviv. 2012;6(3):345–56.PubMedCrossRef Hauglann B, et al. A cohort study of permanently reduced work ability in breast cancer patients. J Cancer Surviv. 2012;6(3):345–56.PubMedCrossRef
17.
go back to reference de Boer AGEM, et al. Interventions to enhance return-to-work for cancer patients. Cochrane Database Syst Rev. 2015;2015(9):CD007569–CD007569.PubMedPubMedCentral de Boer AGEM, et al. Interventions to enhance return-to-work for cancer patients. Cochrane Database Syst Rev. 2015;2015(9):CD007569–CD007569.PubMedPubMedCentral
18.
go back to reference Lee MK, et al. Three-year prospective cohort study of factors associated with return to work after breast cancer diagnosis. J Occup Rehabil. 2017;27(4):547–58.PubMedCrossRef Lee MK, et al. Three-year prospective cohort study of factors associated with return to work after breast cancer diagnosis. J Occup Rehabil. 2017;27(4):547–58.PubMedCrossRef
19.
go back to reference İzci F, et al. Impact of personality traits, anxiety, depression and hopelessness levels on quality of life in the patients with breast cancer. Eur J Breast Health. 2018;14(2):105–11.PubMedPubMedCentral İzci F, et al. Impact of personality traits, anxiety, depression and hopelessness levels on quality of life in the patients with breast cancer. Eur J Breast Health. 2018;14(2):105–11.PubMedPubMedCentral
20.
go back to reference Wei C-W, Wu M-L, Tung H-H. Relationships between health literacy and quality of life among survivors with breast cancer. Int J Nurs Pract. 2021;27(2):e12922.PubMedCrossRef Wei C-W, Wu M-L, Tung H-H. Relationships between health literacy and quality of life among survivors with breast cancer. Int J Nurs Pract. 2021;27(2):e12922.PubMedCrossRef
21.
22.
go back to reference Oldenburg J, Fosså SD, Dahl AA. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res. 2006;15(5):791–800.PubMedCrossRef Oldenburg J, Fosså SD, Dahl AA. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res. 2006;15(5):791–800.PubMedCrossRef
23.
go back to reference Aaronson NK, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.PubMedCrossRef Aaronson NK, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.PubMedCrossRef
24.
go back to reference Sprangers MA, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756–68.PubMedCrossRef Sprangers MA, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756–68.PubMedCrossRef
26.
go back to reference Spitzer RL, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.PubMedCrossRef Spitzer RL, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.PubMedCrossRef
27.
go back to reference Thewes B, et al. The Concerns About Recurrence Questionnaire: validation of a brief measure of fear of cancer recurrence amongst Danish and Australian breast cancer survivors. J Cancer Surviv. 2015;9(1):68–79.PubMedCrossRef Thewes B, et al. The Concerns About Recurrence Questionnaire: validation of a brief measure of fear of cancer recurrence amongst Danish and Australian breast cancer survivors. J Cancer Surviv. 2015;9(1):68–79.PubMedCrossRef
28.
go back to reference Grov EK, et al. The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors. Acta Oncol. 2009;48(6):842–9.PubMedCrossRef Grov EK, et al. The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors. Acta Oncol. 2009;48(6):842–9.PubMedCrossRef
29.
go back to reference Tambs K, et al. Pedigree analysis of Eysenck Personality Questionnaire (EPQ) scores in monozygotic (MZ) twin families. Behav Genet. 1991;21(4):369–82.PubMedCrossRef Tambs K, et al. Pedigree analysis of Eysenck Personality Questionnaire (EPQ) scores in monozygotic (MZ) twin families. Behav Genet. 1991;21(4):369–82.PubMedCrossRef
30.
go back to reference Grav S, et al. The relationship among neuroticism, extraversion, and depression in the HUNT study: in relation to age and gender. Issues Ment Health Nurs. 2012;33(11):777–85.PubMedCrossRef Grav S, et al. The relationship among neuroticism, extraversion, and depression in the HUNT study: in relation to age and gender. Issues Ment Health Nurs. 2012;33(11):777–85.PubMedCrossRef
31.
go back to reference Grov EK, Dahl AA. Is neuroticism relevant for old cancer survivors? A controlled, population-based study (the Norwegian HUNT-3 survey). Support Care Cancer. 2021;29(7):3623–32.PubMedCrossRef Grov EK, Dahl AA. Is neuroticism relevant for old cancer survivors? A controlled, population-based study (the Norwegian HUNT-3 survey). Support Care Cancer. 2021;29(7):3623–32.PubMedCrossRef
32.
go back to reference Finbråten HS, et al. Establishing the HLS-Q12 short version of the European Health Literacy Survey Questionnaire: latent trait analyses applying Rasch modelling and confirmatory factor analysis. BMC Health Serv Res. 2018;18(1):506.PubMedPubMedCentralCrossRef Finbråten HS, et al. Establishing the HLS-Q12 short version of the European Health Literacy Survey Questionnaire: latent trait analyses applying Rasch modelling and confirmatory factor analysis. BMC Health Serv Res. 2018;18(1):506.PubMedPubMedCentralCrossRef
33.
go back to reference World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation. Geneva: World Health Organization; 2000. World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation. Geneva: World Health Organization; 2000.
34.
go back to reference Godin G, Jobin J, Bouillon J. Assessment of leisure time exercise behavior by self-report: a concurrent validity study. Can J Public Health. 1986;77(5):359–62.PubMed Godin G, Jobin J, Bouillon J. Assessment of leisure time exercise behavior by self-report: a concurrent validity study. Can J Public Health. 1986;77(5):359–62.PubMed
35.
go back to reference Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci. 1985;10(3):141–6.PubMed Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci. 1985;10(3):141–6.PubMed
36.
go back to reference Schmitz KH, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7):1409–26.PubMedCrossRef Schmitz KH, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7):1409–26.PubMedCrossRef
40.
go back to reference Reinertsen KV, et al. Predictors and course of chronic fatigue in long-term breast cancer survivors. J Cancer Surviv Res Pract. 2010;4(4):405–14.CrossRef Reinertsen KV, et al. Predictors and course of chronic fatigue in long-term breast cancer survivors. J Cancer Surviv Res Pract. 2010;4(4):405–14.CrossRef
41.
go back to reference de Ruiter MB, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32(8):1206–19.PubMedCrossRef de Ruiter MB, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32(8):1206–19.PubMedCrossRef
42.
go back to reference Fosså SD, et al. Stability of health-related quality of life in the Norwegian general population and impact of chronic morbidity in individuals with and without a cancer diagnosis. Acta Oncol. 2007;46(4):452–61.PubMedCrossRef Fosså SD, et al. Stability of health-related quality of life in the Norwegian general population and impact of chronic morbidity in individuals with and without a cancer diagnosis. Acta Oncol. 2007;46(4):452–61.PubMedCrossRef
43.
go back to reference Mirandola D, et al. Longitudinal assessment of the impact of adapted physical activity on upper limb disability and quality of life in breast cancer survivors from an Italian cohort. Support Care Cancer. 2018;26(2):329–32.PubMedCrossRef Mirandola D, et al. Longitudinal assessment of the impact of adapted physical activity on upper limb disability and quality of life in breast cancer survivors from an Italian cohort. Support Care Cancer. 2018;26(2):329–32.PubMedCrossRef
44.
go back to reference Mustian KM, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 2017;3(7):961–8.PubMedPubMedCentralCrossRef Mustian KM, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 2017;3(7):961–8.PubMedPubMedCentralCrossRef
45.
go back to reference Campbell KL, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51(11):2375–90.PubMedPubMedCentralCrossRef Campbell KL, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51(11):2375–90.PubMedPubMedCentralCrossRef
46.
47.
go back to reference Hakanen JJ, Lindbohm M-L. Work engagement among breast cancer survivors and the referents: the importance of optimism and social resources at work. J Cancer Surviv. 2008;2(4):283–95.PubMedCrossRef Hakanen JJ, Lindbohm M-L. Work engagement among breast cancer survivors and the referents: the importance of optimism and social resources at work. J Cancer Surviv. 2008;2(4):283–95.PubMedCrossRef
48.
go back to reference Larsen IK, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–31.PubMedCrossRef Larsen IK, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–31.PubMedCrossRef
Metadata
Title
Work status changes and associated factors in a nationwide sample of Norwegian long-term breast cancer survivors
Authors
Synne-Kristin Hoffart Bøhn
K. F. Vandraas
C. E. Kiserud
A. A. Dahl
L. Thorsen
M. Ewertz
H. C. Lie
R. Falk
K. V. Reinertsen
Publication date
22-03-2022
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 2/2024
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-022-01202-2

Other articles of this Issue 2/2024

Journal of Cancer Survivorship 2/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine